BACKGROUND Sometimes, in pediatric oncology, it is difficult to differentiate the relapse of primary tumor from other diagnoses such as post-ischemic lesions or fungal abscess, without performing an organ biopsy. In addition, patients frequently are not under clinical conditions to be biopsied, mainly due to febrile neutropenia. A growing number of studies has focused on the use of Positron emi...

Background: Febrile neutropenia is one of the most serious adverse events in patients with hematological malignancies and chemotherapy. The routine use of fluoroquinolone prophylaxis in patients with hematological malignancies is controversial. Therefore, we prospectively evaluated the efficacy and safety of prophylactic use of garenoxacin for febrile neutropenia. Patients and Methods: Consecut...

Breast cancer is the most common cancer in women worldwide. Doxorubicin-based chemotherapy is used to treat breast cancer patients; however, neutropenia is a common hematologic side effect and can be life-threatening. The ABCB1 and SLC22A16 genes encode proteins that are essential for doxorubicin transport. In this study, we explored the effect of 2 common polymorphisms in ABCB1 (rs10276036 C/T...

Review Questions: What are the prognostic indicators predictive of chemotherapy-induced febrile neutropenia outcomes (favourable and unfavourable) among adult cancer patients? Background: Febrile Neutropenia (FN) is a major complication for cancer patients undergoing chemotherapy.1 It is associated with significant morbidity and mortality. Standard patient care includes prolonged hospitalizatio...

The use of colony-stimulating factors became an autonomous approach in complex supportive care blood tumors. By indications granulocyte factor (G-CSF) it is possible to reduce neutropenic period, perform optimal timing therapy, decrease a number infection complications. development and active new G-CSF drug formulation – pegfilgrastim do not the duration period significantly, but reduced freque...

Febrile neutropenia is a relatively frequent event in cancer patients treated with chemotherapy. In the United States, an estimated 60,000 patients a year are hospitalized for febrile neutropenia and neutropenia related infections (Cagganio et al., 2005). Our single institution data in previous two studies have shown the frequency to be ranging from 10 to 12 per month (Lal et al., 2008; Shaikh ...